Unlock instant, AI-driven research and patent intelligence for your innovation.

Allosteric trans-splicing group i ribozyme whose activity of target-specific rna replacement is controlled by theophylline

A technology of trans-splicing and theophylline, which is applied in the determination/inspection of enzymes, transferases, and microorganisms, and can solve the problem that the therapeutic effect will not be maximized.

Active Publication Date: 2010-03-31
IND ACADEMIC COOP FOUND DANKOOK UNIV
View PDF1 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

When the mutated gene product does have a dominant negative effect, the therapeutic effect by traditional methods may not be maximized

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Allosteric trans-splicing group i ribozyme whose activity of target-specific rna replacement is controlled by theophylline
  • Allosteric trans-splicing group i ribozyme whose activity of target-specific rna replacement is controlled by theophylline
  • Allosteric trans-splicing group i ribozyme whose activity of target-specific rna replacement is controlled by theophylline

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0075] Hereinafter, exemplary embodiments of the present invention will be described with reference to the accompanying drawings, but the present invention is not particularly limited thereto.

[0076] Reference Example 1: Preparation of Substrate (hTERT) RNA

[0077] To prepare target RNA, primers described in SEQ ID NO: 9 (5'-GGGGAATTCTAATACGACTCACTATAGGGCAGGCAGCGCTGCGTCCT-3') and primers described in SEQ ID NO: 10 (5'-CGGGATCCCTGGCGGAAGGAGGGGGCGGCGGG-3') were paired with hTERT-containing hTERT-1 The pCl-neo vector (exon 1-2) of the DNA sequence to +218th was subjected to PCR amplification to obtain a DNA fragment encoding hTERT RNA. The DNA fragments thus prepared are transcribed into RNA in vitro. Add DNA template (3 μ g), 10x transcription buffer, 10 mM DTT (Sigma), 0.5 mM ATP, GTP, CTP, and UTP (Roche), 80 U of RNase inhibitor (Cosco (Kosco)), 200U of T7 RNA polymerase (Ambion), and diethylpyrocarbonate water (DEPC-H 2 O) to a final volume of 100 μl and then mixed. T...

Embodiment 7

[0091] Reference Example 7: Cell Culture

[0092] Incubate hTERT-positive cell lines in 5% CO 2 293 (human kidney / normal), HT-29 (colon / colon adenocarcinoma), Capan-1 (pancreas / adenocarcinoma) and HepG2 (liver / hepatocellular carcinoma) were used as reference, and place hTERT-negative cell lines in 5% CO 2 Cultured at 37°C in an incubator with IMR-90 (lung / fibroblast / normal) and SK-LU1 (lung / adenocarcinoma) American Type Collection (ATCC) as reference.

[0093] Reference Example 8: Confirmation of Specificity and Efficiency of Trans-splicing Aptamase in Cell Lines

[0094] 1) The test of the optimum concentration of theophylline

[0095] 293 cells in a 35mm dish in 3×10 5 The concentrations were inoculated and grown to approximately 80% confluency. In this case, growing 293 cells were transfected with 1 μg of Mu P9 6t8t with liposomal LipofectAMINE (Invitrogen). The transfected 293 cells were cultured in increasing concentrations of theophylline or caffeine (0.1 mM, 0.3 m...

Embodiment 1

[0111] Example 1: Preparation of a trans-splicing ribozyme with theophylline aptamer attached and specifically targeting hTERT RNA

[0112] As the basic trans-splicing ribozyme backbone for the development of allosteric ribozymes, a type I intronic ribozyme that specifically recognizes the +21nt site of hTERT and has a target The antisense sequence of 300nt of RNA is annealed P1, P10 and extended IGS ( figure 2 ). This ribozyme was observed to induce specific apoptosis in hTERT-expressing cancer cells by specifically expressing hTERT RNA in cells and animal models (Mol. Ther. 2005; 12:824, Mol Ther .2008;16:74)

[0113] To prepare theophylline-dependent allosteric ribozymes, theophylline RNA aptamer (Science 1994; 263:1425) used as the acceptor region of theophylline was simultaneously attached to either of the P6 or / and P8 regions or Both, this plays an important role in RNA folding for the catalytic function of the hTERT-specific T / S ribozyme developed by the applicant's...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Provided is an allosteric trans-splicing group I ribozyme whose target-specific RNA replacement activity is controlled by theophylline, wherein the hTERT-targeting trans-splicing ribozyme recognizes mRNA of human telomerase reverse transcriptase (hTERT) as a cancer-specific RNA transcript to bind a theophylline aptamer to an hTERT target trans-splicing ribozyme via a communication module, the hTERT target trans-splicing ribozyme having a verified trans-splicing ability. The allosteric trans-splicing group I ribozyme may be useful to selectively diagnose only cancer cells that express target hTERT RNA, or induce their apoptosis since the activity of the allosteric trans-splicing group I ribozyme is dependentIy controlled by theophylline to correct target hTERT RNA by the trans-splicing reaction.

Description

technical field [0001] The present invention relates to an allosteric trans-splicing type I ribozyme whose target-specific ribonucleic acid substitution activity is regulated by theophylline. Background technique [0002] Eager attempts have been made to develop gene therapy technology as a new therapeutic technique to treat incurable human diseases by conducting research on molecular genetic causes and factors of incurable human diseases due to gene mutations. However, there are many unsolved problems in the current gene therapy technology. [0003] Gene therapy, which has been widely used to treat genetic diseases, is made by transferring the normal gene corresponding to the mutated gene into the appropriate cells of the patient (Morgan, R.A. and Anderson, W.F.1993, Human Gene Therapy. Annual Review of Biochemistry 62:191-217 (Morgan, R.A. and Anderson, W.F. 1993, Human gene therapy. Annu. Rev. Biochem. 62:191-217)). Theoretically, in order to obtain a therapeutic effect...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/00
CPCG01N2333/9005C12N2310/1241C12N2310/16C12Y207/07049C12N15/1137C12N15/111C12N2310/3519G01N33/573C12N2310/124A61P35/00A61P43/00C12Q1/6886
Inventor 李城旭张善英金朱玄
Owner IND ACADEMIC COOP FOUND DANKOOK UNIV